The answer is provided by FDA’s 2025 Drug Trials Snapshots Summary Report. The report covers 46 novel drug approvals and roughly 26,000 participants across pivotal trials, organized by therapeutic area rather than a single aggregate narrative. Half (23 out of 46) of these approvals were for the treatment of rare or orphan diseases (i.e., diseases…
Kathy Saunders, senior vice president of revenue cycle management at Redefine, speaks about partnership with AI orchestration company Adonis
Using claims data from the 2023 Merative MarketScan Commercial Claims Database, this Peterson-KFF analysis describes the most common diagnoses for inpatient treatment and total associated costs, including patients’ out-of-pocket share.
Ipsen is acquiring Kartos Therapeutics to get navtemadlin, which has reached Phase 3 testing in the blood cancer myelofibrosis. The Kartos oral small molecule takes a novel approach to restoring the function of p53, a tumor-suppressing protein. The post Ipsen’s $450M Deal Brings Drug That Could Make a Standard Blood Cancer Therapy Better appeared first…
This news release highlights that a KFF analysis finds that 3.8 million Medicare beneficiaries met the criteria to be eligible for the new Medicare GLP-1 Bridge, based on claims data from 2023. The temporary program will provide coverage of three GLP-1 drugs used for weight reduction and weight management to eligible Medicare beneficiaries.
This policy watch discusses a recent Tennessee law that requires the sharing of data for applicants and/or enrollees for the state’s public assistance programs who do not have a qualified immigration status with immigration authorities, including for those enrolled in the state’s Children’s Special Services program, which serves children with disabilities.
Medicare has launched a temporary program covering GLP-1s for obesity for people with Medicare, known as the Medicare GLP-1 Bridge. This analysis estimates the number of Medicare Part D enrollees who could potentially qualify for the Bridge program by meeting all of the eligibility criteria, based on claims data from 2023.
OCHIN researchers describe project designed to improve risk estimates by combining clinical information with patients’ lived experiences
The July 1 changes are being framed as student loan policy. But they raise a larger question about what kind of labor, and whose labor, America is willing to invest in. The post Federal Loan Policy Is Pricing Women Out of Healthcare’s Most Critical Roles appeared first on MedCity News.
Current AI tools often increase the disruption that radiologists already experience from using non-integrated platforms. The post Radiologists Need AI That Works Where They Work, Not Standalone Software appeared first on MedCity News.